All News

May 22, 2019
Bicycle Therapeutics Announces Pricing of Initial Public Offering

May 9, 2019
Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline

May 7, 2019
Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund

April 24, 2019
Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema

April 24, 2019
Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumour-targeted Bispecific Bicycles at Peptides Congress

April 2, 2019
Bicycle Therapeutics to Present at ELRIG’s Research & Innovation 2019 Conference

March 29, 2019
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

March 18, 2019
Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman

March 5, 2019
Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours, at World ADC 2019

February 20, 2019
Bicycle Therapeutics Strengthens Executive Team with Key Changes

February 14, 2019
Bicycle Therapeutics Announces Publication of its Paper Demonstrating Utility of Bicycles® as Imaging Agents

February 12, 2019
Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

November 21, 2018
Bicycle Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference

November 14, 2018
Bicycle Therapeutics Named Best New Drug Developer at 2018 World ADC Awards

November 12, 2018
Bicycle Therapeutics’ Founder Sir Gregory Winter to Deliver Keynote Address at the 2018 Protein and Antibody Engineering (PEGS) Summit Europe

November 8, 2018
Bicycle Therapeutics to Present at Jefferies 2018 London Healthcare Conference

November 1, 2018
Bicycle Therapeutics Strengthens Leadership Team with Appointment of Phil Jeffrey, Ph.D., as SVP Pre-Clinical Development

October 17, 2018
Bicycle Therapeutics Announces Presentation at the Royal Society

October 3, 2018
Bicycle Therapeutics’ Founder Sir Gregory Winter Awarded Nobel Prize in Chemistry

May 31, 2018
Bicycle Therapeutics Announces Formation Of Scientific Advisory Board

May 31, 2018
Bicycle Therapeutics and Cancer Research UK Announce Presentation at 2018 American Society of Clinical Oncology Meeting

May 29, 2018
Bicycle Therapeutics to Present at Jefferies 2018 Global Healthcare Conference

May 25, 2018
Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with Thrombogenics

May 24, 2018
Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

April 3, 2018
Bicycle Therapeutics to Present New BT1718 Data in the “New Drugs on the Horizon” Session at the 2018 American Association for Cancer Research Meeting

March 20, 2018
Bicycle Therapeutics Promotes Michael Skynner, Ph.D., to Chief Operating Officer

March 6, 2018
Bicycle Therapeutics to Present at Cowen and Company 38^th Annual Health Care Conference

February 13, 2018
Bicycle Therapeutics and Cancer Research UK announce initiation of first clinical study of a bicyclic peptide (Bicycle®)

January 4, 2018
Bicycle Therapeutics secures an Innovate UK grant to develop the next generation of antibiotics

December 6, 2017
Bicycle Therapeutics and Cancer Research UK named Best Partnership Alliance of the Year at 2017 Scrip Awards

October 26, 2017
Bicycle Therapeutics to present preclinical data on lead molecule BT1718 at the AACR-NCI-EORTC International Cancer Conference

October 12, 2017
Bicycle Therapeutics recognised with multiple biotech industry awards

September 26, 2017
Bicycle therapeutics strengthens senior management team with appointment of Maria Koehler, M.D., Ph.D., As Chief Medical Officer

September 6, 2017
Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for Haemophilia and Sickle Cell Disease

August 1, 2017
Bicycle Therapeutics expands leadership team with appointment of Lee Kalowski as Chief Financial Officer

June 1, 2017
Bicycle Therapeutics closes £40 million ($52 million) in Series B financing to advance clinical pipeline

April 20, 2017
Bicycle Therapeutics announces a candidate preclinical milestone in its ophthalmology alliance with Thrombogenics

April 3, 2017
Bicycle Therapeutics announces presentations at the 2017 American Association for Cancer Research Annual Meeting

March 29, 2017
Bicycle Therapeutics is named winner of Business Weekly’s Disruptive Technology Award 2017

March 2, 2017
Bicycle Therapeutics to present at Cowen and Company 37th Annual Health Care Conference

January 5, 2017
Bicycle Therapeutics appoints Nicholas Keen, Ph.D., as Chief Scientific Officer

December 21, 2016
Bicycle Therapeutics is named winner of Fierce Innovation Award

December 15, 2016
Cancer Research UK and Bicycle Therapeutics collaborate to trial new therapy for advanced solid tumours

December 1, 2016
Bicycle Therapeutics announces broad partnership with AstraZeneca to develop bicyclic peptides (Bicycles®)

November 28, 2016
Bicycle Therapeutics to present preclinical data at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

October 11, 2016
Bicycle Therapeutics appoints Peter U. Park, Ph.D., as Vice President of Oncology Research

July 18, 2016
Bicycle Therapeutics appoints Stephen J. Hoffman, M.D., Ph.D., as Board Chairman

May 23, 2016
Bicycle Therapeutics establishes US operations and appoints Rosamond Deegan, MBA, as President and Chief Business Officer

May 5, 2016
Bicycle Therapeutics strengthens product development capabilities with key leadership appointments

September 21, 2015
Bicycle Therapeutics announces appointment of CEO

October 14, 2014
Bicycle Therapeutics announces £20M ($32M) million financing for drug development